Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

Abstract Background Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). P...

Full description

Bibliographic Details
Main Authors: Lauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, Ivan Bièche, Amanda Bartolini Silveira, Marc Michel, Delphine Loirat, Paul Cottu, Luc Cabel, Coraline Dubot, Romain Geiss, Francesco Ricci, Anne Vincent-Salomon, Charlotte Proudhon, François-Clément Bidard
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Breast Cancer Research
Subjects:
Circulating tumor DNA
Breast cancer
Palbociclib-fulvestrant
Treatment follow-up
Precision medicine
Online Access:https://doi.org/10.1186/s13058-021-01411-0

Internet

https://doi.org/10.1186/s13058-021-01411-0

Similar Items